| This past week the biopharma industry lost longtime analyst Mark Schoenebaum and FibroGen founder and CEO Thomas Neff. Schoenebaum had previously taken medical leave from Evercore ISI in 2016, and subsequently left the firm in 2017. He was admired as much for his personality and sense of humor as for his hard work, according to his former colleague Umer Raffat. Neff’s passing comes as the drug he championed, the oral anemia med roxadustat, nears regulatory filings in the U.S. and Europe, and after its second approval in China. Neff lead FibroGen for 26 years following its founding in 1993. | |
|
Featured Story | | | Monday, August 26, 2019 Mark Schoenebaum, the longtime biopharma analyst admired as much for his personality as for his work, died over the weekend, wrote Umer Raffat, an Evercore ISI colleague that Schoenebaum mentored, on Sunday evening. The cause of death wasn’t specified, but he had taken medical leave from Evercore in 2016 and left the firm in 2017. |
|
|---|
|
Top Stories Of The Week Monday, August 26, 2019 Thomas Neff founded FibroGen in 1993 and has led the company for decades. Now, the company is searching for its next leader with his unexpected death over the weekend. Neff's passing comes as FibroGen nears key filings. Friday, August 23, 2019 A phase 2 trial of GlaxoSmithKline’s BCMA drug has hit its primary endpoint, keeping Hal Barron’s group on track to file for approval in multiple myeloma by the end of the year. Monday, August 26, 2019 Looks like Amgen might not be buying Alexion after all. Instead, it’s beefing up in psoriasis, where it already sells blockbuster TNF inhibitor Enbrel, by snatching up Celgene’s Otezla for $13.4 billion. Tuesday, August 27, 2019 In an inspection of the Illinois manufacturing facility for Novartis’ Zolgensma this year, top FDA officials met with AveXis staff. Although the assay now at the center of a Novartis scandal was discussed, the FDA found the situation “unremarkable.” Tuesday, August 27, 2019 Biobeat received clearance from the FDA for its smartwatch-based patient monitoring device, designed to track a user’s blood pressure and other vital signs without a traditional inflated cuff, alongside a similar 10-day patch worn on the upper torso. Tuesday, August 27, 2019 When I first started being a biopharma reporter back in the recession period of 2009 when Pfizer and Merck were in the midst of megamergers, I remember asking my then-editor a question that really irked him. Tuesday, August 27, 2019 It’s no secret that the two existing PCSK9 cardiovascular drugs on the market, Amgen’s Repatha and Regeneron and Sanofi’s Praluent, are suffering from painfully slow launches. And on top of that, they could soon face a serious threat thanks to a positive phase 3 readout from a more convenient option, one analyst argues. Friday, August 23, 2019 Amgen may be on the verge of acquiring Alexion for $200 per share, a Spanish news site reported Thursday. Analysts say the deal makes sense and would prop up Amgen's top and bottom lines, which are under pressure from biosimilar competition to key drugs Neulasta and Sensipar. Monday, August 26, 2019 A team of researchers at Boston Children's Hospital has developed an innovative way to knock out the oncogene Lipocalin 2 using the editing system CRISPR and has shown its potential for treating triple-negative breast tumors in mice. Resources Sponsored by: Wesco Pharmaceutical Solutions and WBR Insights The regulations and managing processes for hazardous, controlled and rare chemicals and biologics necessary for drug discovery are a huge distraction for R&D labs. Learn from the perspectives of industry executives the pain points and improvements they want in their processes for chemicals and biologics in pharmaceuticals R&D. Sponsored by: Kinaxis Download this life sciences industry spotlight to discover how concurrent planning can help you overcome complex supply chain challenges to drive down costs and improve efficiency. Sponsored by: Patheon, by Thermo Fisher Scientific Patheon, part of Thermo Fisher Scientific, offers advanced API manufacturing technologies such as continuous processing and continuous analytics to deliver high-quality products with well-defined features to meet your timelines and volume requirements. Sponsored by: ICON Understanding the challenges for formulary decision makers and manufacturers. Sponsored by: Veeva This white paper details how leveraging new reporting capabilities, live UAT feedback sessions, and an agile design approach to study builds will save them time and money. Sponsored by: Catalent Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study. Sponsored by: Catalent Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels. Sponsored by: Catalent Download the eBook to explore a proactive approach for clinical supply management. |
